BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21105683)

  • 1. Chemical probes that selectively recognize the earliest Aβ oligomers in complex mixtures.
    Reinke AA; Ung PM; Quintero JJ; Carlson HA; Gestwicki JE
    J Am Chem Soc; 2010 Dec; 132(50):17655-7. PubMed ID: 21105683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into the aggregation mechanism of Aβ(25-40).
    Xiong J; JiJi RD
    Biophys Chem; 2017 Jan; 220():42-48. PubMed ID: 27856006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elucidating the Structures of Amyloid Oligomers with Macrocyclic β-Hairpin Peptides: Insights into Alzheimer's Disease and Other Amyloid Diseases.
    Kreutzer AG; Nowick JS
    Acc Chem Res; 2018 Mar; 51(3):706-718. PubMed ID: 29508987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's protective A2T mutation changes the conformational landscape of the Aβ₁₋₄₂ monomer differently than does the A2V mutation.
    Das P; Murray B; Belfort G
    Biophys J; 2015 Feb; 108(3):738-47. PubMed ID: 25650940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Mechanism and Kinetics of Amyloid-β
    Man VH; He X; Ji B; Liu S; Xie XQ; Wang J
    ACS Chem Neurosci; 2019 Nov; 10(11):4643-4658. PubMed ID: 31660732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stabilization of neurotoxic Alzheimer amyloid-beta oligomers by protein engineering.
    Sandberg A; Luheshi LM; Söllvander S; Pereira de Barros T; Macao B; Knowles TP; Biverstål H; Lendel C; Ekholm-Petterson F; Dubnovitsky A; Lannfelt L; Dobson CM; Härd T
    Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15595-600. PubMed ID: 20713699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unmodified and pyroglutamylated amyloid β peptides form hypertoxic hetero-oligomers of unique secondary structure.
    Goldblatt G; Cilenti L; Matos JO; Lee B; Ciaffone N; Wang QX; Tetard L; Teter K; Tatulian SA
    FEBS J; 2017 May; 284(9):1355-1369. PubMed ID: 28294556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of familial mutations on the monomer structure of Aβ₄₂.
    Lin YS; Pande VS
    Biophys J; 2012 Dec; 103(12):L47-9. PubMed ID: 23260058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A strategy for designing a peptide probe for detection of β-amyloid oligomers.
    Hu Y; Su B; Kim CS; Hernandez M; Rostagno A; Ghiso J; Kim JR
    Chembiochem; 2010 Nov; 11(17):2409-18. PubMed ID: 21031399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arrest of beta-amyloid fibril formation by a pentapeptide ligand.
    Tjernberg LO; Näslund J; Lindqvist F; Johansson J; Karlström AR; Thyberg J; Terenius L; Nordstedt C
    J Biol Chem; 1996 Apr; 271(15):8545-8. PubMed ID: 8621479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid β-Protein Assembly: Differential Effects of the Protective A2T Mutation and Recessive A2V Familial Alzheimer's Disease Mutation.
    Zheng X; Liu D; Roychaudhuri R; Teplow DB; Bowers MT
    ACS Chem Neurosci; 2015 Oct; 6(10):1732-40. PubMed ID: 26244608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stabilization, Assembly, and Toxicity of Trimers Derived from Aβ.
    Kreutzer AG; Yoo S; Spencer RK; Nowick JS
    J Am Chem Soc; 2017 Jan; 139(2):966-975. PubMed ID: 28001392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anti-prion RNA aptamer R12 disrupts the Alzheimer's disease-related complex between prion and amyloid β.
    Iida M; Mashima T; Yamaoki Y; So M; Nagata T; Katahira M
    FEBS J; 2019 Jun; 286(12):2355-2365. PubMed ID: 30916478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mimotope of Aβ oligomers may also behave as a β-sheet inhibitor.
    Zhang YX; Wang SW; Lu S; Zhang LX; Liu DQ; Ji M; Wang WY; Liu RT
    FEBS Lett; 2017 Nov; 591(21):3615-3624. PubMed ID: 28976547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-n oligomers as therapeutic targets of Alzheimer's disease.
    Ono K; Yamada M
    J Neurochem; 2011 Apr; 117(1):19-28. PubMed ID: 21244429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphism of Alzheimer's Abeta17-42 (p3) oligomers: the importance of the turn location and its conformation.
    Miller Y; Ma B; Nussinov R
    Biophys J; 2009 Aug; 97(4):1168-77. PubMed ID: 19686665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.
    Izzo NJ; Staniszewski A; To L; Fa M; Teich AF; Saeed F; Wostein H; Walko T; Vaswani A; Wardius M; Syed Z; Ravenscroft J; Mozzoni K; Silky C; Rehak C; Yurko R; Finn P; Look G; Rishton G; Safferstein H; Miller M; Johanson C; Stopa E; Windisch M; Hutter-Paier B; Shamloo M; Arancio O; LeVine H; Catalano SM
    PLoS One; 2014; 9(11):e111898. PubMed ID: 25390368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of Alzheimer's disease-associated Abeta aggregation by rationally designed nonpeptidic beta-sheet ligands.
    Rzepecki P; Nagel-Steger L; Feuerstein S; Linne U; Molt O; Zadmard R; Aschermann K; Wehner M; Schrader T; Riesner D
    J Biol Chem; 2004 Nov; 279(46):47497-505. PubMed ID: 15322133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Hexamer of a Peptide Derived from Aβ
    Kreutzer AG; Spencer RK; McKnelly KJ; Yoo S; Hamza IL; Salveson PJ; Nowick JS
    Biochemistry; 2017 Nov; 56(45):6061-6071. PubMed ID: 29028351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.